Patents by Inventor Catherine Charreyre
Catherine Charreyre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10350287Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.Type: GrantFiled: August 10, 2016Date of Patent: July 16, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Jean-Christophe Audonnet, Jules Maarten Minke, Teshome Mebatsion, Catherine Charreyre
-
Publication number: 20180236056Abstract: The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.Type: ApplicationFiled: April 27, 2017Publication date: August 23, 2018Applicants: MERIAL INC., CHULALONGKORN UNIVERSITYInventors: Sanipa Suradhat, Jean-Christophe Audonnet, Catherine Charreyre
-
Patent number: 9669085Abstract: The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.Type: GrantFiled: May 24, 2012Date of Patent: June 6, 2017Assignees: MERIAL INC., Chulalongkorn UniversityInventors: Sanipa Suradhat, Jean-Christophe Audonnet, Catherine Charreyre
-
Publication number: 20170087242Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.Type: ApplicationFiled: August 10, 2016Publication date: March 30, 2017Applicant: MERIAL, INC.Inventors: Jean-Christophe Audonnet, Jules Maarten Minke, Teshome Mebatsion, Catherine Charreyre
-
Publication number: 20120315294Abstract: The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.Type: ApplicationFiled: May 24, 2012Publication date: December 13, 2012Inventors: Sanipa Suradhat, Jean-Christophe Audonnet, Catherine Charreyre
-
Publication number: 20120301479Abstract: The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Inventors: Jean-Christophe AUDONNET, Jules Maarten MINKE, Teshome MEBATSION, Catherine CHARREYRE
-
Patent number: 7691368Abstract: The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic surfactant. In another embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a non-ionic lipophilic surfactant, a mineral oil and a non-ionic hydrophilic ethoxylated fatty alcohol. The present invention also encompasses a method of making a vaccine composition using the adjuvant of the instant invention, the vaccine composition so obtained and methods of use.Type: GrantFiled: April 15, 2005Date of Patent: April 6, 2010Assignee: Merial LimitedInventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre, Claude Jean Marie Roulet
-
Publication number: 20100062019Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: ApplicationFiled: September 10, 2009Publication date: March 11, 2010Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Patent number: 7608279Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: GrantFiled: February 7, 2008Date of Patent: October 27, 2009Assignee: Merial LimitedInventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Publication number: 20080187555Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: ApplicationFiled: February 7, 2008Publication date: August 7, 2008Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Patent number: 7371395Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: GrantFiled: July 26, 2004Date of Patent: May 13, 2008Assignee: Merial LimitedInventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Publication number: 20080014221Abstract: The invention provides a novel method of vaccination of a pig against Mycoplasma hyopneumoniae by administering to a weaned piglet or a sow, a single dose of an effective amount of a Mycoplasma hyopneumoniae vaccine. The Mycoplasma hyopneumoniae vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine.Type: ApplicationFiled: February 27, 2007Publication date: January 17, 2008Inventors: Gregory Royer, Russell Howser, Catherine Charreyre, Francis Milward
-
Publication number: 20070009550Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: September 15, 2006Publication date: January 11, 2007Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Charreyre, Gilles Chappuis, Francis McNeilly, Li Wang, Lorne Babiuk, Andrew Potter, Philip Willson
-
Publication number: 20060292177Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: July 12, 2006Publication date: December 28, 2006Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Charreyre, Gilles Chappuis, Francis McNeilly, Li Wang, Lorne Babiuk, Andrew Potter, Philip Willson
-
Publication number: 20060286642Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: July 12, 2006Publication date: December 21, 2006Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Charreyre, Gilles Chappuis, Francis McNeilly, Li Wang, Lorne Babiuk, Andrew Potter, Philip Willson
-
Publication number: 20060233831Abstract: The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic surfactant. In another embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a non-ionic lipophilic surfactant, a mineral oil and a non-ionic hydrophilic ethoxylated fatty alcohol. The present invention also encompasses a method of making a vaccine composition using the adjuvant of the instant invention, the vaccine composition so obtained and methods of use.Type: ApplicationFiled: April 15, 2005Publication date: October 19, 2006Inventors: Alexis Parisot, Stephanie Desgouilles-Blechet, Catherine Charreyre, Claude Roulet
-
Publication number: 20060029617Abstract: The present invention is based on the discovery of novel species of the genus Helicobacter that are associated with gastro-esophageal ulceration in pigs. In particular, a novel species, H. cerdo, has been used as a source of antigenic material for the development of vaccine for the treatment of the gastro-esophageal disorders. Most advantageously, the novel Helicobacter and the porcine circoviruses associated with PMWS in pigs are useful for providing combination vaccines whereby immunogens derived from both types of pathogens may be codelivered to the target animal to stimulate the generation of protective antibodies and immunity. The invention, therefore, provides vaccines that are useful for the tratment of gastro-esophageal ulceration and PMWS in porcines. The present invention includes, therefore, multivalent immunogenic compositions and vaccines, multivaccine kits, and combined immunization or vaccination methods which make it possible to use such combined immunization or vaccination programmes.Type: ApplicationFiled: April 15, 2005Publication date: February 9, 2006Inventors: Catherine Charreyre, John Ellis, Olivier Martinon
-
Publication number: 20060002952Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: September 1, 2005Publication date: January 5, 2006Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Charreyre, Gilles Chappuis, Francis McNeilly, Li Wang, Lorne Babiuk, Andrew Potter, Philip Willson
-
Publication number: 20050079185Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: ApplicationFiled: July 26, 2004Publication date: April 14, 2005Inventors: Alexis Guy Parisot, Stephanie Desgouilles-Blechet, Catherine Charreyre
-
Publication number: 20050058653Abstract: Porcine circovirus-2 (PCV-2) is a recently identified agent wherein the potential spectrum of PCV-2-associated disease has been expanded by evidence of vertical and sexual transmission and associated reproductive failure in swine populations. PCV-2 was isolated from a litter of aborted piglets from a farm experiencing late term abortions and stillbirths. Severe, diffuse myocarditis was present in one piglet associated with extensive immunohistochemical staining for PCV-2 antigen. Variable amounts of PCV-2 antigen were also present in liver, lung and kidney of multiple fetuses.Type: ApplicationFiled: February 17, 2004Publication date: March 17, 2005Inventors: John Ellis, Gordon Allan, Brian Meehan, Edward Clark, Deborah Haines, Lori Hassard, John Harding, Catherine Charreyre, Gilles Chappuis, George Krakowka, Jean-Christophe Audonnet, Francis McNeilly